FacebookX(旧Twitter)Instagram

業績一覧（学会発表）

論文業績学会発表賞罰・研究助成

学会発表

国際学会

  1. Recommendations on abdominal ultrasound in inflammatory bowel disease (20-min pre-recorded presentation video) AOCC2021 Oct 14-16, 2021. Kobayashi T
  2. Challenge case III (20-min pre-recorded presentation video) AOCC2021 Oct 14-16, 2021. Kobayashi T
  3. IL-1R-mediated mechanisms of IL-10 production by gut macrophages. AOCC2021 Oct 14-16, 2021. Hibi N et al
  4. Predicting risk factors of steroid dependence after initial steroid therapy in ulcerative colitis. AOCC2021 Oct 14-16, 2021. Miyatani Y et al
  5. Usefulness of colestimide for postoperative refractory diarrhea in patients with Crohn's disease. AOCC2021 Oct 14-16, 2021. Hojo A et al
  6. Sustained Reduction of IL-23-Related Cytokines IL-17A and IL-22 in a Phase 2 Study of Mirikizumab in the Treatment of Patients With Moderately-to-Severely Active Ulcerative Colitis. ECCO2020 Feb 12-17, 2020. Kobayashi T et al
  7. Session Abbvie Esai Korea Inc.sponsored symposium1 “Evidence to support optimal IBD management in clinical practice.” AOCC2020 Dec 12.16-18, 2020. Kobayashi T
  8. Optimal therapeutic strategies: thinking out of the box De-escalation of therapy in patients with quiescent IBD. AOCC2020 Dec 12.16-18, 2020. Kobayashi T
  9. Capsule scoring of ulcerative colitis (CSUC) is useful for monitoring inactive ulcerative colitis. Crohn's and colitis congress 2019 Feb 7-11, 2019. Matsubayashi M et al
  10. Accuracy of Doppler transabdominal ultrasound in assessing disease severity and extent in IBD. ECCO2019 Mar 7, 2019. Sagami S et al
  11. Withdrawal of thiopurines in Crohn’s disease treated with scheduled adalimumab maintenance: a prospective randomised clinical trial (DIAMOND2) ECCO2019 Mar 7, 2019. Hibi T et al
  12. Safety and effectiveness of adalimumab treatment in 1523 patients with ulcerative colitis: Results from a prospective, multi-centre ,observational study. ECCO2019 Mar 7, 2019. Hibi T et al
  13. Scientific Session 5: IBD around the world. ECCO2019 Mar 8, 2019. Hibi T (Chair)
  14. Extended induction treatment with mirikizumab in patients with moderately to severely active ulcerative colitis: results from a Phase 2 trial. ECCO2019 Mar 8, 2019. Hibi T et al
  15. Amiselimod, a selective S1P receptor modulator in Crohn’s disease patients: a proof-of-concept study. ECCO2019 Mar 8, 2019. Hibi T et al
  16. Maintenance treatment with mirikizumab, a p19-directed IL-23 antibody: 52-week results in patients with moderately-to-severely active ulcerative colitis. ECCO2019 Mar 9, 2019 Hibi T et al
  17. Does switching between 5-aminosalicylates affest thiopurine metabolism and clinical outcomes in patients with ulcerative colitis? Digestive Disease Week 2019 San Diego May 18-21, 2019. Hibi T,Kobayashi T et al
  18. Capsule Endoscopy for IBD Plenary Session 1(Diagnosis of IBD) AOCC2019台北(台湾) Jun 14-16, 2019. Kobayashi T
  19. Clinical characteristics and outcomes of 5-ASA intolerance in patients with ulcerative colitis. AOCC2019台北(台湾) Jun 14-16, 2019. Kiyohara H et al
  20. Efficacy and safety of anti-fractalkine monoclonal antibody,E6011,in patients with Crohn's Disease who had lost response to anti-TNFa agents: A multicentre,open-label,Phase 1/2 study. ECCO2018 Feb 16, 2018. Hibi T et al
  21. Incidence risks of colorectal cancer, non-melanoma skin cancers, and non-Hodgkin lymphoma in Japanese patients with ulcerative colitis based on a large-scale claims database. ECCO2018 Feb 16, 2018. Hibi T,Kobayashi T et al
  22. “Risks of malignancies in Japanese patients with ulcerative colitis based on the large-scale claims databases” ECCO2018 Feb 19, 2018. Kobayashi T
  23. Challenging case II. 6th annual meeting of Asian Organization for Crohn’s and Colitis Jun 22, 2018. Kobayashi T
  24. Mechanism-based treatment strategy for IBD: How to use new medicines properly “JAK inhibitors” FALK symposium 212 Sep 7-8, 2018 Kobayashi T
  25. Clinical characteristics and outcomes of 5-ASA intolerance in patients with ulcerative colitis. FALK symposium 212 Sep 7-8, 2018. Kiyohara H et al
  26. Accuracy of transabdominal ultrasound in assessing disease activity in ulcerative colitis. FALK symposium 212 Sep 7-8, 2018. Hibi T,Kobayashi T et al
  27. Emerging Therapies in IBD “New kids on the block” the role of small molecules in IBD. The 3rd APAGE Clinical IBD Forum Cebu 2018 Sep 22, 2018. Kobayashi T
  28. High-fat low-carbohydrate diet influence the intestinal tract and microbiota of mice. CEBU 2018 3rd APAGE Clinical Forum on IBD Sep 22, 2018. Kuronuma S et al
  29. Different genetic aspects of IBD in Asia. The 5th IBD Summit Forum Dalian,China Nov 25-56, 2017. Hibi T
  30. Association between pharmacokinetics of adalimumab and disease outcome in Japanese patients with biologics naive Crohn’s Disease: A subanalysis of DIAMOND trial. Feb 15-18, 2017. Hibi et al
  31. Efficacy of anti-TNF for internal fistula in Crohn’s Disease – results from a retrospective multicenter cohort study.ECCO2017 Feb 15-18, 2017. Hibi,Kobayashi et al
  32. Combination therapy with adalimumab and immunomodulators decreases incidence of intestinal resection in Crohn’s Disease patients previously treated with infliximab: A large,multicentre cohort study.ECCO2017 Feb 15-18, 2017. Hibi,Kobayashi et al
  33. Histological risk factors to predict clinical relapse in Ulcerative Colitis in mucosal healing.ECCO2017 Feb 15-18, 2017. Hibi,Kobayashi et al
  34. Clinical features of chronic enteropathy associated with SLCO2A1 gene (CEAS)ECCO2017 Feb 15-18, 2017. Hibi et al
  35. Submucosal injection of the oligonucleotide STNM01 is able to induce clinical remission,mucosal healing and histological response in left-sided Ulcerative Colitis patients with Moderate-to-Severe disease. ECCO2017 Feb 17, 2017. Hibi et al
  36. Comparison of endoscopic responses to adalimumab monotherapy and combination therapy with azathioprine in patients with Crohn's Disease:A sub-analysis of DIAMOND trial.ECCO2017 Feb 17, 2017. Hibi et al
  37. Usefulness of fecal calprotectin in detecting the early response to induction therapy in ulcerative colitis. ACG 2016, Las Vegas, USA, Oct 18 (poster) Oct 18,2016 Kobayashi
  38. Adalimumab 80 mg Every Other Week in Japanese Patients with Crohn's Disease Who Lost Response to Maintenance Therapy.AOCC2016 Jul 9, 2016. Hibi et al
  39. Efficacy and safety of golimumab subcutaneous administration in Japanese patients with moderately to severely active ulcerative colitis.AOCC2016 Jul 9, 2016. Hibi et al
  40. Effects of CYP3A5 genotype on efficacy and safety of tacrolimus in refractory ulcerative colitis-experience from a tertiary referral center.AOCC2016 Jul 9, 2016. Hibi,Kobayashi et al
  41. Chronic enteropathy associated with SLCO2A1 gene,encoding prostaglandin transporter(CEAS):relationship with primary hypertrophic osteoarthropathy.AOCC2016 Jul 9, 2016. Hibi et al
  42. Factors associated with the first trough level of infliximab at week 2 that predicts short- and long-term outcomes.DDW2016, San Diego, USA May 21, 2016. Hibi,Kobayashi et al
  43. What do we know about the impact of nutrients on the mucosal immune system?Asia America Assembly of IBD Apl 7, 2016. Hibi,Kobayashi et al
  44. Faecal calprotectin and S100A12 detect the early response to treatment by quantifying colonic inflammation in patients with Ulcerative Colitis.11th Congress of ECCO RAI Amsterdam Mar 16-19, 2016. Hibi,Kobayashi et al
  45. Factors associated with the first trough level of infliximab at week 2 that predicts short-and long-term outcomes in Ulcerative Colitis. 11th Congress of ECCO RAI Amsterdam Mar 19, 2016. Hibi,Kobayashi et al
  46. Mid-to long-term stability and associated prognostic factors of adalimumab treatment for 1189 patients with Crohn's Disease:A multicentre cohort study.11th Congress of ECCO RAI Amsterdam Mar 18, 2016. Hibi,Kobayashi et al
  47. Comparison of adalimumab monotherapy and a combination with azathioprine for patients with Crohn's Disease: A prospective,multicentre,open-labeled clinical trial (DIAMOND study).11th Congress of ECCO RAI Amsterdam Mar 18, 2016. Hibi et al
  48. First Trough Level of Infliximab at Week 2 Predicts Future Outcomes of Induction Therapy in Icerative Colitis: A Post-hoc Analysis of a Multicenter Prospective Randomized Controlled Trial . ACG2015 Oct 20, 2015. Hibi,Kobayashi et al
  49. Usefulness of fecal S100A12 in defining mucosal healing in ulcerative colitis. 3rd AOCC, Beijing, China June 20, 2015. Kobayashi
  50. Infliximab therapy for Japanese patients with Ulcerative Colitis : Efficacy,safety,and association between serum infliximab levels and early respnse in a randomized, double-blind,placebo-controlled study.10th Congress of ECCO CCIB Barcelona Feb 18-21, 2015. Hibi et al
  51. Twice-daily budesonide rectal foam induces complete mucosal healing in Japanese patients with mild to moderate Ulcerative Colitis : Results of multicentre, randomised, double-blind,placebo-controlled trial.10th Congress of ECCO CCIB Barcelona Feb 18-21, 2015. Hibi et al
  52. Impact of Inflammatory Bowel Disease on Japanese patients` lives : International comparison of patients` views.10th Congress of ECCO CCIB Barcelona Feb 18-21, 2015 Hibi et al
  53. Usefulness of faecal S100A12 in defining mucosal healing in Ulcerative Colitis.10th Congress of ECCO CCIB Barcelona Feb 18-21, 2015. Hibi,Kobayashi et al
  54. A large-scale, prospective, observational study of leukocytapheresis for ulcerative colitis: Treatment outcomes of 847 patients in clinical practice. 2nd AOCC, Seoul, June 20, 2014. Kobayashi et al
  55. 「(tentative)How to use IFX in UC in 2014?The need for new treatment algorithms」FEBG UC Expert Meeting 2014 In Chicago May 6, 2014. Hibi(chair)
  56. Anti-TNFs in UC: who,when,how?FEBG UC Expert Meeting May 6, 2014. Hibi(chair)
  57. Timely use of biologics in UC.UC Seminar 2014 in Chicago May 5, 2014. Hibi(chair)
  58. How to manage UC in a Long term perspective.(Draft) Lecture meeting at DDW May 4, 2014. Hibi(chair)
  59. Efficacy, Safety, and Demographics Factor of Adalimumab Therapy in 1693 Japanese Crohn's Disease Patients.DDW Chicago May 3-6, 2014. Hibi et al
  60. Percutaneous Endoscopic Gastrostomy Under Steady Pressure Automatically Controlled Endoscopy. (SPACE)DDW Chicago May 3-6, 2014. Hibi et al
  61. Efficacy and Safety of Rikkunshito, a Japanese Herbal Medicine, on the Treatment of Functional Dyspepsia: A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study.DDW Chicago May 3-6, 2014. Hibi et al
  62. AJM300, an Oral α4 Integrin Antagonist, for Active Ulcerative Colitis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2A Study.DDW Chicago May 3-6, 2014. Hibi et al
  63. Current and future treatments of IBD in Japan Are they different from Westerns?PUMCH International Digestive Disease Forum Apl 19, 2014. Hibi
  64. Feasibility of the second-generation colon capsule endoscopy in patients with ulcerative colitis with a reduced preparation regimen. 1st AOCC, Tokyo, June 14, 2013. (Oral) Kobayashi et al
  65. NFIL3 deficient mice develop IL-12/23 driven spontaneous colitis. 1st AOCC, Tokyo,June 13, 2013. (Oral) Kobayashi et al
  66. Feasibility of the second-generation colon capsule endoscopy in patients with ulcerative colitis with a reduced preparation regimen. DDW2013, Orlando, FL, May 20, 2013. (Poster) Kobayashi et al
  67. Amino acids and inflammatory bowel disease-as a therapeutic target and a novel biomarker. 8th Asia Pacific Conference, Tokyo, June 10, 2013. Hibi
  68. The future perspective and issues of IBD in Asia, 1th AOCC, Tokyo, June 13-14, 2013. Hibi
  69. Diffrences between treatment guidelines in IBD, Falk Symposium 188, Germany, June 8, 2013. Hibi
戻る
サイトマップサイトマップページトップページトップ